Evaluating Aranesp® in Subjects With End Stage Renal Disease onChronic Hemodialysis

Summary

The purpose of this study is to assess the Aranesp® dose administered intravenously (IV) once weekly to maintain hemoglobin (Hgb) levels in hemodialysis subjects who are either recombinant human erythropoietin (rHuEPO) naïve or subjects converted from rHuEPO therapy administered IV thrice weekly (TIW).

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications